IMMU-36. HYPERGLYCEMIA SUPPRESSES MACROPHAGE ACTIVITY AND INHIBITS GLIOMA INVASION IN DIABETIC MICE

Ian Zhang,Huili Liu,Hui Zhou,Leying Zhang,Behnam Badie,Darya Alizadeh
DOI: https://doi.org/10.1093/neuonc/nox168.494
2017-01-01
Neuro-Oncology
Abstract:Patients with malignant glioma (MG) are often treated with corticosteroids to reduce cerebral edema, but chronic use of steroids may cause glucose intolerance and development of type 2 diabetes (Db). Individuals with Db not only have significantly higher likelihood of developing malignant tumors, but also, have a higher risk of cancer-related mortality than non-Db patients. The goal of this study was to evaluate the effect of hyperglycemia on glioma growth in mouse models. Because MG are heterogeneous tumors with both invasive and “nodular” phenotypes, two different syngeneic glioma models were examined in streptozotocin-induced Db mice. We found that in the GL261 gliomas that typically grow as “nodular” tumors, hyperglycemia activated receptor for advanced glycation endproducts (RAGE) by upregulating HMGB1 expression, and promoted tumor growth irrespective of tumor microenvironment (TME). Similarly, the K-Luc gliomas, which are invasive and elicit a robust macrophage infiltration, grew faster in subcutaneous (s.c.) location in Db mice. However, intracranial (i.c.) K-luc gliomas were smaller and less invasive in hyperglycemic mice. Our studies showed that a reduction in K-Luc growth in the brains of Db mice was mostly due to the abrogation of inflammatory responses and suppression of pro-inflammatory cytokines such as IL-1b and IL-6 in TME. We conclude that hyperglycemia may enhance glioma growth by activating the RAGE pathway and suppressing antitumor responses. But, suppression of tumor inflammation may also inhibit glioma growth by abrogating i.c. tumor invasion under hyperglycemic conditions.
What problem does this paper attempt to address?